Thymosin Alpha-1 TA1 2mg/vial 5mg/vial

Thymosin Alpha-1, also known as TA1 or Tα1, is a naturally occurring peptide fragment that was discovered in 1972 and researched for its potential action within the context of studies relating to cystic fibrosis, infection (e.g., tuberculosis, cytomegalovirus), respiratory disorders, chronic hepatitis, and cancer. It is also referred to as Thymalfasin when synthetically developed. Originally, research on Thymosin Alpha-1 centered around its potential role in immune modulation. It is hypothesized that it might increase levels of Major Histocompatibility Complex (MHC) class I molecules and boost cytokine production, key components of the immune system that may enhance immune responses.[1][2] There is also a possibility that it might improve the activity of natural killer cells, which target virus-infected cells and tumors. Furthermore, it might enhance the expression of specific markers on T cells that are considered critical for their identification and function in the immune system, indicating a significant role in immune regulation. Thymosin Alpha-1 is also thought to possibly increase the presence of high-affinity interleukin-2 receptors on cell surfaces, potentially leading to the vigorous activation and proliferation of T lymphocytes, elements of immune response. There is speculation that it may affect both T-helper and cytotoxic T-cell populations, deemed essential for eliminating infected cells. Additionally, it might prompt the differentiation of thymocytes—precursor cells in the thymus—and peripheral blood lymphocytes into mature immune cells, increase natural killer cell numbers, and promote cytokine-driven inflammatory responses. Research also explores its potential role in enhancing macrophage efficiency—cells that engulf and digest pathogens—and in regulating the activity of alpha thrombin, a protein involved in blood clotting, highlighting its broad potential on immune function.